Kyprolis 60 Injection

Description of Kyprolis 60 (Carfilzomib 60 mg) injection

Carfilzomib, a component of Kyprolis 60 injection, is an antineoplastic drug which belongs to the group of proteasome inhibitors. It is mainly used to treat hematologic malignancies and mostly multiple myeloma. The mechanism of action of the drug entails the selective blockage of the proteasomal activity in cancerous cells. The proteasome under physiological conditions facilitates the degradation of damaged/dispensable proteins; inhibition of such a process results in the accumulation of aberrant proteins and thus breaks cellular homeostasis. The consequenceant proteotoxic stress leads to the development of apoptosis in cancer cells and therefore hinders the progression of tumours. Carfilzomib is regularly administered to patients who received other therapeutic options to treat multiple myeloma in the past.

Indications of Kyprolis 60 (Carfilzomib 60 mg) injection

Carfilzomib is used in the treatment of Multiple myeloma Relapsed or refractory and Multiple myeloma patients that have already undergone one or more lines of treatment. It can be taken either as a standalone drug or as a drug combination with other anticancer drugs like dexamethasone or immunomodulatory agents according to the clinical regimen.

Mechanism of action of Kyprolis 60 (Carfilzomib 60 mg) injection

Its therapeutic action is caused by irreversible inhibition of chymotrypsin-like activity of the 26S proteasome. In turn this makes the degradation of intracellular proteins, which are involved in the control of cell-cycle progression and apoptosis, depend on the activity of proteasomes. Proteasome inhibition triggers the accumulation of damaged proteins in malignant cells, putting cellular strains and disrupting cellular signaling cascades which are essential to neoplastic growth. These are eventually disrupted to induce apoptosis of the malignant plasma cells and prevent tumour advancement.

How to consume Kyprolis 60 (Carfilzomib 60 mg) injection

The carfilzomib is treated as an intravenous infusion technique under the control of competent health professionals. The dosage regime is based on the treatment programme chosen by the oncologist. It is commonly administered in a series of courses during a few weeks and corticosteroid pre-medication before infusion can be applied to minimise the reactions to the infusion. The dose and the period of treatment are determined by the body surface area of the patient, the stage of the disease, and therapy reaction.

Side Effects of Kyprolis 60 (Carfilzomib 60 mg) injection

1. Common side effects

• Flattened or general muscular weakness.
• Nausea and vomiting
• Dyspnea
• Anemia
• Diarrhoea
• Fever

2. Serious side effects

• Severe thrombocytopenia
• Heart related complications, such as heart failure.
• Hypertension
• Pulmonary complications
• Renal dysfunction

3. Rare side effects

• Tumour lysis syndrome
• Extreme hypersensitivity responses.

Safety Advice for Kyprolis 60 (Carfilzomib 60 mg) injection

Patients that receive Carfilzomib must be regularly monitored, including blood count, kidney examination, hepatic enzymes tests, and blood pressure cheques.

Breastfeeding: Treatment should stop breastfeeding due to the possibility of the drug being transferred to the breast milk and causing harm to the infant.

Pregnancy: It is advised that carfilzomib is not used in pregnancy since it may cause fetal toxicity. During the therapy, effective contraception is recommended..

Alcohol: The use of alcohol should be reduced since it can increase hepatic stress/fatigue.

Liver: drug should be used cautiously by persons with pre-existing liver disease, who should have hepatic monitoring periodically.

Lungs: The respiratory symptoms like dyspnea or persistent coughing should be immediately reported.

Kidney: The patients who are renal-impaired require the close monitoring because renal functioning might worsen during the course of the treatment.

Driving: The patient can experience fatigue and dizziness; therefore, the patients are not advised to drive or operate heavy machinery in case of these symptoms.

Interaction of Kyprolis 60 (Carfilzomib 60 mg) injection

• Drug–Drug Interaction

Ketoconazole × Carfilzomib
Ketoconazole could increase the toxicity risk through increasing the systemic exposure to Carfilzomib by blocked hepatic metabolism.

Rifampicin × Carfilzomib
Rifampicin stimulates the liver to release enzymes and can decrease the plasma levels of Carfilzomib, thus decreasing treatment effectiveness.

Phenytoin × Carfilzomib
Phenytoin can lower the levels of drugs by triggering of metabolic pathways.

Clarithromycin × Carfilzomib
Clarithromycin may also boost the shouldering of the drugs with increased chances of side effects.

Warfarin × Carfilzomib
It is also justified to use special caution since thrombocytopenia can increase the risk of bleeding.

Other Myelosuppressive Drugs × Carfilzomib
The concomitant usage might enhance bone marrow suppression and risk of infection.

• Drug–Food Interaction

Grapefruit and grapefruit juice are not to be taken as they can disrupt drug metabolism and increase the level of systemic drugs.

• Drug–Disease Interaction

Bone marrow suppression:

Carfilzomib may significantly change the activity of bone-marrow and, thus, inhibit the formation of platelets, erythrocytes, and leukocytes. The occurrence of severe anaemia, thrombocytopenia and neutropenia is thus predisposed to patients with underlying bone-marrow insufficiency or other hematologic diseases. Complete blood counts should continuously be monitored during therapy. Temporary discontinuation or dose reduction of the agent can be justified in case of severe cytopenia.

Cardiovascular disease:

Carfilzomib is associated with cardiovascular related conditions such as hypertension, heart failure, myocardial ischemia, arrhythmias. The patients who present antecedent cardiac disease, uncontrolled hypertension, or history of cardiac events are at risk of an increased risk of cardiac adverse events during the treatment. The assessment of the cardiac functioning and the constant monitoring of blood pressure are recommended before and during the treatment.

Renal impairment:

Carfilzomib may impair renal functions. Some of the patients might deteriorate and renal performance or electrolyte imbalances. Close follow-up of subjects with antecedent renal impairment using regular kidney functional evaluations must be performed. Proper hydration is often prescribed to reduce the possibility of kidney problems.

Liver dysfunction:

Since Carfilzomib undergoes hepatic metabolism, patients with hepatic conditions are likely to have increased drug exposures and toxicities. Tests of liver functioning are to be assessed prior to starting treatment and periodically checked during treatment. Patients with moderate or severe liver impairment might be required to undergo a dose adjustment.

Active infections:

Since Carfilzomib has the ability to suppress the immune system and decrease the number of leukocytes, patients who have constant infections may have their conditions worsened. Careful therapeutic administration should be done in individuals who come in with active bacterial, viral, or fungal infections. Early medical assessment should be considered in case the patient exhibits signs of fever, chills, or pharyngitis which is intractable..

Contraindication of Kyprolis 60 (Carfilzomib 60 mg) injection

Carfilzomib should not be used in patients experiencing hypersensitivity to the drug or any of its ingredients. The agent should also not be used in pregnancy and those with uncontrolled severe infections. Patients with high cardiovascular disease should be carefully assessed.

Dosage of Kyprolis 60 (Carfilzomib 60 mg) injection

The dosage is computed based on the body surface area of the patient. It is normally given as intravenous infusion as per a treatment regimen given by the oncologist. Dose modifications can be recommended into response to patient adverse effects and tolerance.

Storage of Kyprolis 60 (Carfilzomib 60 mg) injection

The ambient temperature that the vial is stored in should be within the recommended range, it must not be exposed to extreme moisture or heat. The drug should not be taken out of the pack until the time it is to be used and it should be stored where children cannot see it.

Missed Dose of Kyprolis 60 (Carfilzomib 60 mg) injection

Since Carfilzomib is administered in a clinical case, it has rare missed doses. In case a dosage is not taken at a specified time, the prescribing physician will decide on how the dosing schedule should be changed.

Other General Information of Kyprolis 60 (Carfilzomib 60 mg) injection

Carfilzomib patients should be well hydrated and have balanced diets. Follow-up appointments are necessary to cheque the response to treatment and identify the negative effects at an early stage. Persistent fatigue, fever, chest pain, or acute swelling are considered any form of atypical symptoms that should be reported to the healthcare provider immediately. Patients too are expected to notify their doctor about all other concurrent drugs or supplements so as to avoid any drug interactions.

FAQs of Kyprolis 60 (Carfilzomib 60 mg) injection

1. In what way is Carfilzomib applied in the treatment of multiple myeloma?

Carfilzomib prevents the proteasome route in the malignant plasma cells to lead to accumulation of toxic proteins and eventual cancer cell death.

2. Is Carfilzomib able to impair heart functioning?

Some of them might develop cardiac complications (e.g., heart failure or hypertension), hence cardiovascular monitoring is necessary during treatment.

3. What is the rationale of hydration in treatment?

Sufficient hydration is useful in avoiding renal complications and in minimising the possibility of tumour-lysi syndrome.

4. Will the use of Carfilzomib trigger fatigue?

Yes, fatigue is one of the side effects, which are reported frequently, and patients should have enough rest during treatment.

5. Does it use Carfilzomib as a single-drug therapy?

Depending on the treatment regimen, it can be used either as a single agent, or in combination with other anti-cancer agents.

Fact Box of Kyprolis 60 (Carfilzomib 60 mg) injection

References

• FDA Prescribing Information – Kyprolis (Carfilzomib)
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202714s027lbl.pdf
• National Cancer Institute – Carfilzomib
  https://www.cancer.gov/about-cancer/treatment/drugs/carfilzomib
• DrugBank – Carfilzomib
  https://go.drugbank.com/drugs/DB08889
• European Medicines Agency – Kyprolis Product Information
  https://www.ema.europa.eu/en/documents/product-information/kyprolis-epar-product-information_en.pdf